Opus Genetics (acquired in 2024)) Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $25.8M

  • Investors
  • 1

Opus Genetics (acquired in 2024)) General Information

Description

Provider of a gene therapy intended to treat rare retinal degenerative diseases. The company offers adeno-associated virus-based gene therapies and helps in tackling manufacturing obstacles standing in the way of treatments, enabling businesses to provide access to treatments for blinding conditions efficiently.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 8 Davis Drive
  • Durham, NC 27709
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 8 Davis Drive
  • Durham, NC 27709
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Opus Genetics (acquired in 2024)) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 22-Oct-2024 $25.8M Completed Generating Revenue
3. Early Stage VC (Series A) 27-Jun-2023 Completed Clinical Trials - Phase 1
2. Seed Round 20-Aug-2021 $19M $19M Completed Clinical Trials - Phase 1
1. University Spin-Out 01-Jan-2021 Completed Startup
To view Opus Genetics (acquired in 2024))’s complete valuation and funding history, request access »

Opus Genetics (acquired in 2024)) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Opus Genetics (acquired in 2024))’s complete cap table history, request access »

Opus Genetics (acquired in 2024)) Patents

Opus Genetics (acquired in 2024)) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026122826-A1 Methods and compositions for improving visual performance under mesopic light conditions using phentolamine Pending 05-Dec-2024
WO-2026055508-A1 Methods and compositions for treating and preventing the progression of intermediate age-related macular degeneration and related conditions Pending 06-Sep-2024
WO-2025194083-A1 Compositions comprising an apx3330 hemicalcium salt monohydrate and therapeutic uses thereof Pending 14-Mar-2024
EP-4559900-A1 Phentolamine mesylate and therapeutic uses thereof Pending 21-Nov-2023
US-20250162995-A1 Phentolamine mesylate and therapeutic uses thereof Pending 21-Nov-2023 A61K31/417
To view Opus Genetics (acquired in 2024))’s complete patent history, request access »

Opus Genetics (acquired in 2024)) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Opus Genetics (acquired in 2024)) Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bios Partners Venture Capital Minority
Manning Family Foundation Limited Partner Minority
Michigan Capital Network Venture Capital Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
To view Opus Genetics (acquired in 2024))’s complete investors history, request access »

Opus Genetics (acquired in 2024)) FAQs

  • When was Opus Genetics (acquired in 2024)) founded?

    Opus Genetics (acquired in 2024)) was founded in 2021.

  • Where is Opus Genetics (acquired in 2024)) headquartered?

    Opus Genetics (acquired in 2024)) is headquartered in Durham, NC.

  • What is the size of Opus Genetics (acquired in 2024))?

    Opus Genetics (acquired in 2024)) has 13 total employees.

  • What industry is Opus Genetics (acquired in 2024)) in?

    Opus Genetics (acquired in 2024))’s primary industry is Drug Discovery.

  • Is Opus Genetics (acquired in 2024)) a private or public company?

    Opus Genetics (acquired in 2024)) is a Private company.

  • What is the current valuation of Opus Genetics (acquired in 2024))?

    The current valuation of Opus Genetics (acquired in 2024)) is .

  • What is Opus Genetics (acquired in 2024))’s current revenue?

    The current revenue for Opus Genetics (acquired in 2024)) is .

  • How much funding has Opus Genetics (acquired in 2024)) raised over time?

    Opus Genetics (acquired in 2024)) has raised $23.5M.

  • Who are Opus Genetics (acquired in 2024))’s investors?

    Bios Partners, Manning Family Foundation, Michigan Capital Network, and Retinal Degeneration Fund have invested in Opus Genetics (acquired in 2024)).

  • When was Opus Genetics (acquired in 2024)) acquired?

    Opus Genetics (acquired in 2024)) was acquired on 22-Oct-2024.

  • Who acquired Opus Genetics (acquired in 2024))?

    Opus Genetics (acquired in 2024)) was acquired by Opus Genetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process